Nurix Therapeutics, Inc. · NASDAQ:NRIX
Nurix Therapeutics — EHA 2025 Investor Event
35 slides from Nurix Therapeutics's conference presentation, Jun 12, 2025
Slide 1: Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA
Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA European Hematological Association Investor Event June 12, 2025
Slide 2: Forward-looking statements
This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,” “believe,” “could,” “estimat
Slide 3: EHA 2025: Two Clinical Updates for Bexobrutideg
EHA 2025: Two Clinical Updates for Bexobrutideg 3 FRIDAY, JUNE 13 (18:30 - 19:30 CEST) Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study Presenting aut
Slide 4: Agenda
Agenda 4 Dr. Talha Munir, MBChB, Ph.D. Consulting Hematologist, Leeds Teaching Hospitals, NHS Trust Bexobrutideg demonstrates rapid and durable clinical responses in relapsed/ refractory CLL: updated findings from an ongoing Phase 1a study Bexobrutideg (NX-5948) shows high clinical activity and tole
Slide 5: Bexobrutideg Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study 1Zulfa Omer, 2Alexey Danilov, 3Francesco Forconi, 4Nirav Shah, 5Graham P. Collins, 6Shuo Ma, 7Jane Ro
Slide 6: Bexobrutideg: A Small Molecule BTK Degrader Addressing Unmet Need in CLL
6 • The current standard of care in CLL focuses on utilizing the inhibitors of two key signaling pathways: BTK and BCL2 • Unmet need still exists in the CLL treatment landscape: – Covalent and non-covalent BTKi resistance mutations are found in more than half of patients who progress on BTKi therapi
Slide 7: NX-5948-301: trial design (CLL cohorts)
NX-5948-301: trial design (CLL cohorts) Phase 1a/b Trial in Adults with Relapsed/Refractory B-cell Malignancies 7 Data cutoff: 12 Mar 2025BCL2i, BCL2 inhibitor; BTKi, BTK inhibitor; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; QD, once daily; SLL
Slide 8: Phase 1a CLL Patient Disposition and Demographics
Phase 1a CLL Patient Disposition and Demographics CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma Patient disposition Patient demographics 8 Characteristics Patients (n=48) Median age, years (range) 68.5 (35–88) Sex, n (%) Male 32 (66.7) Ethnicity, n (%) Hispanic or Latino 3 (6.3)
Slide 9: Baseline disease characteristics
Baseline disease characteristics: Phase 1a Patient Population with Unmet Medical Need: Multiple Prior Lines of Therapy and High Prevalence of Baseline Mutations 9 Characteristics Patients with CLL/SLL (n=48) ECOG PS, n (%) 0 1 19 (39.6) 29 (60.4) CNS involvement, n (%) 5 (10.4) Median prior lines of
Slide 10: Bexobrutideg Safety Profile in Relapsed/Refractory CLL
TEAEs in ≥10% of patients or Grade ≥3 TEAEs or SAEs in >1 patient: Phase 1a Bexobrutideg Safety Profile: Well Tolerated in Patients with Relapsed/Refractory CLL 10 TEAEs, n (%) Patients with CLL/SLL (n=48) Any grade Grade ≥3 SAEs Purpura/contusiona 22 (45.8) – – Diarrhea 15 (31.3) 2 (4.2) – Fatigueb
Slide 11: Clinically Meaningful Objective Responses in Relapsed/Refractory CLL
CLL, chronic lymphocytic leukemia; CR, complete response; iwCLL, International Workshop on CLL; ORR, objective response rate; PD, progressive disease; PR, partial response; PR-L, partial response with rebound lymphocytosis; SD, stable disease Bexobrutideg overall response assessment: Phase 1a Clinic
Slide 12: Broad Activity Independent of Baseline Mutational Profile
Broad Activity Independent of Baseline Mutational Profile ATM, Ataxia-telangiectasia mutated; BTK, Bruton’s tyrosine kinase; BTKi, BTK inhibitor; CLL, chronic lymphocytic leukemia; CNS, central nervous system; iwCLL, International Workshop on CLL; NOTCH1, neurologic locus notch homolog protein 1; PL
Slide 13: Bexobrutideg Demonstrates Durable Response in Relapsed/Refractory CLL
Bexobrutideg Demonstrates Durable Response in Patients with Relapsed/Refractory CLL (n=48) BCL2i, BCL2 inhibitor; BTKi, BTK inhibitor; cBTKi, covalent BTKi; CI, confidence interval; CIT, chemo/chemo-immunotherapies; CR, complete response; ncBTKi, non-covalent BTKi; NE, not evaluable; NR, not reached
Slide 14: Rapid and Sustained Decrease in Lymph Node Size
14 Data cutoff: 12 Mar 2025 Rapid and Sustained Decrease in Lymph Node Size in Patients Treated with Bexobrutideg Percent change from baseline in sum of product diameters in patients with CLL CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; PR-L, PR with rebou
Slide 15: Conclusions
Conclusions • Bexobrutideg (NX-5948) is a novel small molecule that degrades well-validated CLL target BTK by utilizing the ubiquitin-proteasome pathway. • In the fully enrolled Phase 1a CLL portion of the NX-5948-301 study, as of the 12 March 2025 data cut: – Median follow-up was 9.0 months, and mo
Slide 16: Bexobrutideg Shows High Clinical Activity in Waldenström Macroglobulinemia
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia 1Dima El-Sharkawi, 2David Lewis, 3Astrid Pulles, 4Zulfa Omer, 5Talha Munir, 6Graham P. Collins, 7Kim Lint
Slide 17: NX-5948-301 trial design (select NHL cohorts)
NX-5948-301 trial design (focus on select NHL cohorts) Phase 1a/b Trial in Adults with Relapsed/Refractory B-cell Malignancies 17 Phase 1a dose escalation (fully enrolled) Ongoing CLL Phase 1b expansion cohorts (fully enrolled) 50 mg QD 100 mg QD 200 mg QD 300 mg QD 450 mg QD 600 mg QDNHL/WM CLL/SLL
Slide 18: Baseline demographics/disease characteristics
Baseline demographics/disease characteristics Elderly Population with Multiple Prior Lines of Targeted Therapies 18 aPatients could have received multiple prior treatments; bMutation status was gathered from historic patient records BTKi, Bruton’s tyrosine kinase inhibitor; BCL2i, B-cell lymphoma 2
Slide 19: Favorable Safety Profile in Patients with WM
TEAEs in ≥10% of overall population or grade ≥3 TEAEs in ≥1 patient or any SAEs Favorable Safety Profile in Patients with WM: No New Safety Signals 19 aPurpura/contusion includes episodes of purpura or contusion ; bAggregate of 'neutrophil count decreased' or 'neutropenia’; cAggregate of ‘thrombocyt
Slide 20: High Overall Response Rate in Relapsed/Refractory WM
High Overall Response Rate in Patients with Relapsed/Refractory WM MR minor response; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response WM, Waldenström macroglobulinemia WM response-evaluable patients Primary response an
Slide 21: Durable and Deepening Responses in Patients with WM
Durable and Deepening Responses in Patients with WM (n=22) 21 *Ineligible, identified post 1st dose; #Transformed to DLBCL; ǂBased on Kaplan-Meier estimate BCL2i, BCL2 inhibitor; BTKi, BTK inhibitor; cBTKi, covalent BTKi; CI, confidence interval; CR, complete response; ncBTKi, non-covalent BTKi; Pir
Slide 22: Steady Decrease in IgM Levels
Steady Decrease in IgM Levels in Patients Treated with Bexobrutideg 22 Percent change in IgM levels from baseline in patients with WM #Transformed to Diffuse large B cell lymphoma (DLBCL) Response criteria used: Owen RG, Kyle RA, Stone MJ, et al. VIth International Workshop on Waldenström macroglobu
Slide 23: Conclusions
• Bexobrutideg is a novel small molecule BTK degrader that can overcome treatment-emergent BTKi resistance mutations and disrupt BTK scaffolding. • In the ongoing WM portion of the phase 1 NX-5948-301 study, as of the 12 March 2025 data cut: – Median follow-up was 3.7 months, and most patients were
Slide 24: Advancing Toward Registration: Bexobrutideg Clinical Strategy
Paula G. O’Connor, M.D. Chief Medical Officer, Nurix Therapeutics Advancing Toward Registration: Bexobrutideg Clinical Strategy
Slide 25: A New Way to Target BTK: Catalytic and Complete BTKd
A New Way to Target BTK: Catalytic and Complete 25 BTKd: A New Way to Disrupt the BCR Pathway Bexobrutideg: Designed for Superior Characteristics Broad Coverage of Resistance Mutations Efficacy, Safety Benefits in our Ph1a/b Significant unmet need for patients with high-risk molecular features, thos
Slide 26: Advancing Bexobrutideg Globally: Fast Track and PRIME
Enabling accelerated pathways: Fast Track and PRIME Advancing Bexobrutideg Globally 26 CLL WM • U.S. Fast Track Designation from the FDA in January 2024 • Type B End of Phase 1 meeting held with the FDA, key takeaways: • Reviewed dose levels of 200 mg QD and 600 mg QD in the context of Project Optim
Slide 27: Bexobrutideg Poised to Shape the Future Standard of Care in CLL
Initial opportunity in R/R CLL as monotherapy Bexobrutideg Poised to Shape the Future Standard of Care in CLL 27 cBTKi Bexobrutideg 1L CLL R/R CLL 1 Potential expansion opportunities as combo with BCL-2i 2 BexobrutidegcBTKi + BCL-2i 1L CLL R/R CLL cBTKi +/- BCL-2i Bexobrutideg + BCL-2i Bexobrutideg
Slide 28: Nurix Is Advancing Bexobrutideg in CLL with First Pivotal Study in 2025
• Designed to displace BTK inhibitors by degrading both wild-type and mutant BTK, overcoming resistance mechanisms, and addressing scaffolding functions of BTK • Clear demonstration of clinical activity in difficult to treat CLL population • Completed enrollment of Phase 1b dose optimization cohorts
Slide 29: Bexobrutideg and Beyond: Building the Next Generation of TPD Therapies
Arthur T. Sands, M.D., Ph.D. Chief Executive Officer, Nurix Therapeutics Bexobrutideg and Beyond: Building the Next Generation of TPD Therapies
Slide 30: Nurix Pipeline of Proprietary and Partnered Programs
Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs in Oncology and Inflammation & Immunology 30 Program Target Modality Therapeutic area Discovery IND-Enabling Phase 1A Phase 1B/2 Bexobrutideg (NX-5948) BTK Degrader B-cell malignancies Zelebrudomide (NX-2127) BTK-IKZF Degrader B-cel
Slide 31: Bexobrutideg Potential in a Large and Growing CLL Market
Bexobrutideg Has the Potential To Gain a Significant Portion of a Large and Growing CLL Market 31 1. Current sales for BTKis from 2024 product revenues reported by current BTKi manufacturers 2. Projected sales for BTKis from 2028 sales for major markets (US, EU4, UK, Japan) from Clarivate Decision R
Slide 32: Bexobrutideg Positioned to Drive Patient and Commercial Value in CLL
Bexobrutideg Is Well-Positioned to Drive Significant Patient and Commercial Value in CLL Market Based on our Initial CDP 32 ~30K ~16K ~10K CLL Market (Major Markets including US) patients initiating 1st line1 patients initiating 2nd line1 patients initiating 3rd line or later1 ~$6B → >$9B ~$2B → >$5
Slide 33: Targeted Protein Degradation Represents a Whole New Category of Drugs
Targeted Protein Degradation Represents a Whole New Category of Drugs with Major Market Potential 33 Evolution of new therapeutic modalities Antibodies Small Molecule Inhibitors Nucleic Acid-Based Therapies: Antisense, RNAi Gene Therapy, CRISPR Targeted Protein Degradation Drugs Bexobrutideg: the fi
Slide 34: Questions
Questions 34
Slide 35: NURIX
NURIX